Table 2 Respiratory and echocardiographic findings at the initiation of treprostinil
Term infants (n = 11) | Preterm infants (n = 18) | p value | |
|---|---|---|---|
Maximum dose of treprostinil (ng/(min kg)) | 40 [40–52] | 40 [26–50] | 0.453 |
Duration of treprostinil (days) | 24 [22–43] | 24 [16–32] | 0.921 |
Clinical courses during 4 weeks | |||
Mode of ventilation | 0.039 | ||
Non-invasive ventilation | 7 (63.6) | 2 (14.3) | |
Conventional vent | 3 (27.3) | 6 (42.9) | |
HFOV | 1 (9.1) | 6 (42.9) | |
Adding inotropics for hypotension | 1 (9.1) | 6 (46.2) | 0.078 |
Increase in inotropics for hypotension | 5 (45.5) | 12 (66.7) | 0.438 |
Withholding treprostinil due to hypotension | 0 (0) | 1 (5.6) | 1.000 |
Adding another PH drug | 5 (45.5) | 3 (21.4) | 0.389 |
Death | 0 (0) | 7 (38.9) | 0.026 |
Post-treprostinil EchoCG | |||
PAP/sBP | 0.6 [0.4–0.9] | 0.5 [0.4–0.6] | 0.274 |
R to L or bidirectional shunt | 0 (0) | 1 (6.7) | 1.000 |
Interventricular septal deviation | 4 (36.4) | 4 (26.7) | 0.683 |
Ejection fraction (%) | 71.9 [68.7–77.6] | 74.1 [63.9–79.4] | 0.860 |
Any improvement in EchoCG | 11 (100) | 10 (55.6) | 0.012 |